Wave Life Sciences shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral rating. The company also announced the initiation of its Phase 2a clinical trial evaluating WVE-007 in combination with tirzepatide in adults living with obesity.
Login to unlock230characters for free
Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.